1-20 of 296
Naveen Pemmaraju, MD
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Risk Factors Associated with 30-Day Unplanned Readmissions for Adult Acute Myeloid Leukemia (AML)

Veronica A Guerra, MD, Yasmin Alwash, MD, Yan Yuanqing, PhD, Jorge M. Ramos Perez, MD, Guillaume Richard-Carpentier, MD, Ahmad S Alotaibi, Hycienth O Ahaneku, MD MPH, PhD, Bachar Samra, MD, Arrvind Raghunath, MD, Guillermo Montalban-Bravo, MD, Naveen Pemmaraju, MD, Courtney D. DiNardo, MD MSCE, Naval Daver, MD, Gautam Borthakur, MD, Jorge E. Cortes, MD, Farhad Ravandi, MBBS, Hagop M. Kantarjian, MD, Guillermo Garcia-Manero, MD, Tapan M. Kadia, MD
Journal: Blood
Blood (2020) 136 (Supplement 1): 29–30.
DOI: https://doi.org/10.1182/blood-2020-141616
Published: 2020
Journal Articles

Roleof Allogeneic Stem Cell Transplant (ASCT) in Patients (Pts) with Relapsed/Refractory (R-R) Acute Lymphoblastic Leukemia (ALL) Treated with Inotuzumab Ozogamicin (INO) in Combination with Low-Intensity Chemotherapy (mini-hyper-CVD) with or without Blinatumomab (Blina): Results from a Phase 2 Study

Hind Rafei, MD, Hagop M. Kantarjian, MD, Koji Sasaki, MD, Nicholas J. Short, MD, Farhad Ravandi, MBBS, Xuelin Huang, PhD, Joseph D. Khoury, MD, Sa A Wang, MD, Jeffrey L. Jorgensen, MD PhD, Issa F. Khouri, MD, Partow Kebriaei, MD, Richard E. Champlin, MD, Nitin Jain, MD, Bouthaina S. Dabaja, MD, Ghayas C. Issa, MD, Naveen Pemmaraju, MD, Tapan M. Kadia, MD, Shilpa Paul, PharmD, Nadya Jammal, PharmD, Guillermo Garcia-Manero, MD, William G. Wierda, MD PhD, Courtney D. DiNardo, MD MSCE, Naval Daver, MD, Guillermo Montalban-Bravo, MD, Rita Khouri, Patrice Nasnas, MD, Philip A. Thompson, MB, MS, Jovitta Jacob, Meagan Rostykus, RN, Rebecca Garris, MSc, Marina Konopleva, MD PhD, Susan M. O'Brien, MD, Elias Jabbour, MD
Journal: Blood
Blood (2020) 136 (Supplement 1): 39–41.
DOI: https://doi.org/10.1182/blood-2020-143286
Published: 2020
Journal Articles

Interim Results of an Open-Label Phase IB/II Multi-Arm Study of OX40 Agonist Monoclonal Antibody (mAb), Anti-PDL1 Mab, Smoothened Inhibitor, Anti-CD33 Mab, Bcl-2 Inhibitor, and Azacitidine As Single-Agents and As Combinations for Relapsed/Refractory Acute Myeloid Leukemia

Nicholas J. Short, MD, Tapan M. Kadia, MD, Courtney D. DiNardo, MD MSCE, Naveen Pemmaraju, MD, Gautam Borthakur, MD, Guillermo Garcia-Manero, MD, Elias Jabbour, MD, Koji Sasaki, MD, Ghayas C. Issa, MD, Guillermo Montalban-Bravo, MD, Prithviraj Bose, MD, Jan A. Burger, MD PhD, Darla Miller, Lynette Alexander-Williams, Farhad Ravandi, MBBS, Marina Konopleva, MD PhD, Hagop M. Kantarjian, MD, Naval Daver, MD
Journal: Blood
Blood (2020) 136 (Supplement 1): 21–23.
DOI: https://doi.org/10.1182/blood-2020-140153
Published: 2020
Journal Articles

Implications of RAS Mutational Status in Subsets of Patients with Newly Diagnosed Acute Myeloid Leukemia (AML) across Therapy Groups

Daniel Rivera, MD, Hagop M. Kantarjian, MD, Gautam Borthakur, MD, Marina Konopleva, MD PhD, Rashmi Kanagal-Shamanna, MD, Naveen Pemmaraju, MD, Naval Daver, MD, Courtney D. DiNardo, MD MSCE, Koichi Takahashi, MD PhD, Elias Jabbour, MD, Guillermo Montalban-Bravo, MD, Musa Yilmaz, MD, Sherry A. Pierce, BSN, BA, Michael Andreeff, MD PhD, Kapil N. Bhalla, MD, Guillermo Garcia-Manero, MD, Farhad Ravandi, MBBS, Tapan M. Kadia, MD
Journal: Blood
Blood (2020) 136 (Supplement 1): 20–22.
DOI: https://doi.org/10.1182/blood-2020-142043
Published: 2020
Journal Articles

Outcomes of Patients with Myelofibrosis and Favorable Karyotype

Daniel Rivera, MD, Srdan Verstovsek, MD PhD, Prithviraj Bose, MD, Naveen Pemmaraju, MD, Lingsha Zhou, Sherry A. Pierce, BSN, BA, Hagop M. Kantarjian, MD, Zeev E. Estrov, MD, Lucia Masarova, MD
Journal: Blood
Blood (2020) 136 (Supplement 1): 5–6.
DOI: https://doi.org/10.1182/blood-2020-142650
Published: 2020
Journal Articles

AZA + Glutaminase Inhibition with Telaglenastat (CB-839) for Advanced MDS: An Updated Interim Analysis

Kapil Saxena, MD, Marina Konopleva, MD PhD, Tushar D Bhagat, PhD, Veronica A Guerra, MD, Rita Maduike, Stefano Tiziani, PhD, Gautam Borthakur, MD, Elias Jabbour, MD, Naveen Pemmaraju, MD, Tapan M. Kadia, MD, Nicholas J. Short, MD, Jan A. Burger, MD PhD, Steven M. Kornblau, MD, Naval Daver, MD, Kiran Naqvi, MD MPH, Tianyu Cai, PhD, Vinitha Mary Kuruvilla, MSc, Hagop M. Kantarjian, MD, Guillermo Garcia-Manero, MD, Amit Verma, MBBS, Courtney D. DiNardo, MD MSCE
Journal: Blood
Blood (2020) 136 (Supplement 1): 31–32.
DOI: https://doi.org/10.1182/blood-2020-137266
Published: 2020
Journal Articles

Liposomal Cytarabine and Daunorubicin (CPX-351) in Combination with Gemtuzumab Ozogamicin (GO) in Relapsed Refractory (R/R) Patients with Acute Myeloid Leukemia (AML) and Post-Hypomethylating Agent (Post-HMA) Failure High-Risk Myelodysplastic Syndrome (HR-MDS)

Jorge M. Ramos Perez, Tapan M. Kadia, MD, Guillermo Montalban-Bravo, MD, Stefan Faderl, MD, Koji Sasaki, MD, Naval Daver, MD, Courtney D. DiNardo, MD MSCE, Lucia Masarova, MD, Alessandra Ferrajoli, MD, Elias Jabbour, MD, Gautham Borthakur, Hind Al Azzawi, Naveen Pemmaraju, MD, Marina Konopleva, MD PhD, Sherry A. Pierce, BSN, BA, Guillermo Garcia-Manero, MD, Michael Andreeff, MD PhD, Hagop M. Kantarjian, MD, Farhad Ravandi, MBBS, Yesid Alvarado, MD
Journal: Blood
Blood (2020) 136 (Supplement 1): 32–34.
DOI: https://doi.org/10.1182/blood-2020-142570
Published: 2020
Journal Articles

Comparison of Hyper-CVAD Plus Ofatumumab to Hyper-CVAD Plus Rituximab in Patients with Newly Diagnosed Philadelphia Chromosome-Negative CD20-Positive B-Cell Acute Lymphoblastic Leukemia: A Propensity Score Analysis

Kiyomi Morita, MDPhD, Koji Sasaki, MD, Guillaume Richard-Carpentier, MD, Marina Konopleva, MD PhD, Xuelin Huang, PhD, Nicholas J. Short, MD, Nitin Jain, MD, Farhad Ravandi, MBBS, Bouthaina S. Dabaja, MD, Naval Daver, MD, Tapan M. Kadia, MD, Yesid Alvarado, MD, Courtney D. DiNardo, MD MSCE, Ghayas C. Issa, MD, Naveen Pemmaraju, MD, Guillermo Garcia-Manero, MD, Srdan Verstovsek, MD PhD, Sa A Wang, MD, Joseph D. Khoury, MD, Jeffrey L. Jorgensen, MD PhD, Richard E. Champlin, MD, Issa F. Khouri, MD, Partow Kebriaei, MD, Heather M. Schroeder, Maria Khouri, Koichi Takahashi, MD PhD, Susan M. O'Brien, MD, Hagop M. Kantarjian, MD, Elias Jabbour, MD
Journal: Blood
Blood (2020) 136 (Supplement 1): 42–43.
DOI: https://doi.org/10.1182/blood-2020-142121
Published: 2020
Journal Articles

Phase II Study of Venetoclax Added to Cladribine + Low Dose AraC (LDAC) Alternating with 5-Azacytidine Demonstrates High Rates of Minimal Residual Disease (MRD) Negative Complete Remissions (CR) and Excellent Tolerability in Older Patients with Newly Diagnosed Acute Myeloid Leukemia (AML)

Tapan M. Kadia, MD, Gautam Borthakur, MD, Naveen Pemmaraju, MD, Naval Daver, MD, Courtney D. DiNardo, MD MSCE, Koji Sasaki, MD, Ghayas C. Issa, MD, Maro Ohanian, DO, Guillermo Montalban Bravo, MD, Nicholas J. Short, MD, Nitin Jain, MD, Alessandra Ferrajoli, MD, Kapil N. Bhalla, MD, Elias Jabbour, MD, Rashmi Kanagal-Shamanna, MD, Koichi Takahashi, MD PhD, Rashmi Malla, RN, BSN, Kelly Marek, Mark Brandt, BS, Uday R. Popat, MD, Michael Andreeff, MD PhD, Jorge E. Cortes, MD, Guillermo Garcia-Manero, MD, Marina Konopleva, MD PhD, Farhad Ravandi, MBBS, Hagop M. Kantarjian, MD
Journal: Blood
Blood (2020) 136 (Supplement 1): 17–19.
DOI: https://doi.org/10.1182/blood-2020-142092
Published: 2020
Journal Articles

Interim Analysis of the Phase 1b/2 Study of the BCL-2 Inhibitor Venetoclax in Combination with Standard Intensive AML Induction/Consolidation Therapy with FLAG-IDA in Patients with Newly Diagnosed or Relapsed/Refractory AML

Curtis Lachowiez, MD, Marina Konopleva, MD PhD, Tapan M. Kadia, MD, Naval Daver, MD, Sanam Loghavi, MD, Sa A Wang, MD, Maria Adeoti, R.N., Sherry A. Pierce, BSN, BA, Koichi Takahashi, MD PhD, Nicholas J. Short, MD, Koji Sasaki, MD, Gautam Borthakur, MD, Ghayas C. Issa, MD, William G. Wierda, MD PhD, Naveen Pemmaraju, MD, Guillermo Montalban Bravo, MD, Alessandra Ferrajoli, MD, Nitin Jain, MD, Lucia Masarova, MD, Musa Yilmaz, MD, Elias Jabbour, MD, Guillermo Garcia-Manero, MD, Steven M. Kornblau, MD, Farhad Ravandi, MBBS, Hagop M. Kantarjian, MD, Courtney D. Dinardo, MDMSc
Journal: Blood
Blood (2020) 136 (Supplement 1): 18–20.
DOI: https://doi.org/10.1182/blood-2020-134300
Published: 2020
Journal Articles

Quizartinib with Decitabine +/- Venetoclax Is Highly Active in Patients (Pts) with FLT3 -ITD Mutated (mut) Acute Myeloid Leukemia (AML): Clinical Report and Signaling Cytof Profiling from a Phase IB/II Trial

Musa Yilmaz, MD, Hagop M. Kantarjian, MD, Muharrem Muftuoglu, Tapan M. Kadia, MD, Marina Konopleva, MD PhD, Gautam Borthakur, MD, Courtney D. DiNardo, MD MSCE, Naveen Pemmaraju, MD, Nicholas J. Short, MD, Yesid Alvarado, MD, Guillermo Montalban Bravo, MD, Carissa Jurisprudencia, Allison M. Pike, RN, Maro Ohanian, DO, Elias Jabbour, MD, Guillermo Garcia-Manero, MD, Vivian Ruvolo, MS, Farhad Ravandi, MBBS, Michael Andreeff, MD PhD, Naval Daver, MD
Journal: Blood
Blood (2020) 136 (Supplement 1): 19–20.
DOI: https://doi.org/10.1182/blood-2020-142687
Published: 2020
Journal Articles

Prognostic Value of Measurable Residual Disease after Venetoclax and Decitabine in Acute Myeloid Leukemia

Abhishek Maiti, MBBS, Courtney D. DiNardo, MD MSCE, Sa A Wang, MD, Jeffrey L. Jorgensen, MD PhD, Tapan M. Kadia, MD, Naval Daver, MD, Nicholas J. Short, MD, Musa Yilmaz, MD, Naveen Pemmaraju, MD, Gautam Borthakur, MD, Prithviraj Bose, MD, Ghayas C. Issa, MD, Alessandra Ferrajoli, MD, Elias Jabbour, MD, Nitin Jain, MD, Guillermo Garcia-Manero, MD, Maro Ohanian, DO, Koichi Takahashi, MD PhD, Guillermo Montalban-Bravo, MD, Lucia Masarova, MD, Jan A. Burger, MD PhD, Philip A. Thompson, MB, MS, Srdan Verstovsek, MD PhD, Koji Sasaki, MD, Michael Andreeff, MD PhD, Caitlin R. Rausch, PharmD, Kathryn Montalbano, Sherry A. Pierce, BSN, BA, Hagop M. Kantarjian, MD, Marina Konopleva, MD PhD, Farhad Ravandi, MBBS
Journal: Blood
Blood (2020) 136 (Supplement 1): 22–25.
DOI: https://doi.org/10.1182/blood-2020-138773
Published: 2020
Journal Articles

Phase II Study of CPX-351 Plus Venetoclax in Patients with Acute Myeloid Leukemia (AML)

Tapan M. Kadia, MD, Gautam Borthakur, MD, Koichi Takahashi, MD PhD, Courtney D. DiNardo, MD MSCE, Naval Daver, MD, Naveen Pemmaraju, MD, Elias Jabbour, MD, Nitin Jain, MD, Nicholas J. Short, MD, Wei Qiao, PhD, Lade Adewale, Caitlin R. Rausch, PharmD, Sherry A. Pierce, BSN, BA, Yesid Alvarado, MD, Amin M. Alousi, MD, Uday R. Popat, MD, Issa F. Khouri, MD, Guillermo Garcia-Manero, MD, Marina Konopleva, MD PhD, Jorge E. Cortes, MD, Farhad Ravandi, MBBS, Hagop M. Kantarjian, MD
Journal: Blood
Blood (2020) 136 (Supplement 1): 20–22.
DOI: https://doi.org/10.1182/blood-2020-142074
Published: 2020
Journal Articles

Ten-Day Decitabine with Venetoclax Versus Intensive Chemotherapy in Relapsed or Refractory Acute Myeloid Leukemia: A Propensity Score Matched Analysis

Abhishek Maiti, MBBS, Courtney D. DiNardo, MD MSCE, Tapan M. Kadia, MD, Elias Jabbour, MD, Caitlin R. Rausch, PharmD, Naval Daver, MD, Gautam Borthakur, MD, Naveen Pemmaraju, MD, Nicholas J. Short, MD, Musa Yilmaz, MD, Yesid Alvarado, MD, Kathryn S Montalbano, RN, Allison Wade, Rita Maduike, Julio A Guerrero, RN, Kenneth Vaughan, RN, Carol A. Bivins, RN, Sherry A. Pierce, BSN, BA, Farhad Ravandi, MBBS, Hagop M. Kantarjian, MD, Marina Konopleva, MD PhD
Journal: Blood
Blood (2020) 136 (Supplement 1): 30–33.
DOI: https://doi.org/10.1182/blood-2020-138375
Published: 2020
Journal Articles

Outcomes of TP53 -Mutant Acute Myeloid Leukemia with Venetoclax and Decitabine

Kunhwa Kim, MDMPH, Abhishek Maiti, MBBS, Tapan M. Kadia, MD, Farhad Ravandi, MBBS, Naval Daver, MD, Naveen Pemmaraju, MD, Gautam Borthakur, MD, Prithviraj Bose, MD, Ghayas C. Issa, MD, Nicholas J. Short, MD, Musa Yilmaz, MD, Yesid Alvarado, MD, Alessandra Ferrajoli, MD, Elias Jabbour, MD, Nitin Jain, MD, Maro Ohanian, DO, Koichi Takahashi, MD PhD, Philip A. Thompson, MB, MS, Caitlin R. Rausch, PharmD, Kathryn Montalbano, Sherry A. Pierce, BSN, BA, Keyur P. Patel, MBBS, PhD, Guillermo Garcia-Manero, MD, Hagop M. Kantarjian, MD, Courtney D. DiNardo, MD MSCE, Marina Konopleva, MD PhD
Journal: Blood
Blood (2020) 136 (Supplement 1): 33–36.
DOI: https://doi.org/10.1182/blood-2020-140182
Published: 2020
Journal Articles

The Addition of Venetoclax to Ibrutinib Achieves a High Rate of Undetectable Minimal Residual Disease in Patients with High-Risk CLL

Philip A. Thompson, MB, MS, Alessandra Ferrajoli, MD, Nitin Jain, MD, Yan Wang, Christine B Peterson, Naveen Garg, MD, Chongjuan Wei, PhD, Ana Ayala, RN, Tapan M. Kadia, MD, Prithviraj Bose, MD, Naveen Pemmaraju, MD, Nicholas J. Short, MD, Michael J. Keating, MBBS, William G. Wierda, MD PhD
Journal: Blood
Blood (2020) 136 (Supplement 1): 28–29.
DOI: https://doi.org/10.1182/blood-2020-141716
Published: 2020
Journal Articles

Outcomes with Sequential FLT3-Inhibitor (FLT3i) Based Therapies in Patients (pts) with FLT3 -Mutated Acute Myeloid Leukemia (AML) Exposed to Prior FLT3i Based Therapies

Musa Yilmaz, MD, Mansour Alfayez, Tapan M. Kadia, MD, Courtney D. DiNardo, MD MSCE, Gautam Borthakur, MD, Sanam Loghavi, MD, Marina Konopleva, MD PhD, Rashmi Kanagal-Shamanna, MD, Keyur Patel, MD PhD, Elias Jabbour, MD, Guillermo Garcia-Manero, MD, Naveen Pemmaraju, MD, Sherry A. Pierce, BSN, BA, Ghayas C. Issa, MD, Nicholas J. Short, MD, Guillermo Montalban Bravo, MD, Koichi Takahashi, MD PhD, Rita Assi, MD, Ahmad S Alotaibi, Michael Andreeff, MD PhD, Jorge E. Cortes, MD, Hagop M. Kantarjian, MD, Farhad Ravandi, MBBS, Naval Daver, MD
Journal: Blood
Blood (2020) 136 (Supplement 1): 22–24.
DOI: https://doi.org/10.1182/blood-2020-139476
Published: 2020
Journal Articles

The Addition of Navitoclax to Ruxolitinib Demonstrates Efficacy within Different High-Risk Populations in Patients with Relapsed/Refractory Myelofibrosis

Naveen Pemmaraju, MD, Jacqueline S. Garcia, MD, Jalaja Potluri, MD, Leanne Holes, BS, MBA,, Jason Harb, PhD, Paul Jung, PhD, Jessica E. Hutti, PhD, Josef T. Prchal, MD, Srdan Verstovsek, MD PhD, Claire Harrison, DM, FRCP, FRCPath
Journal: Blood
Blood (2020) 136 (Supplement 1): 49–50.
DOI: https://doi.org/10.1182/blood-2020-136938
Published: 2020
Journal Articles

Male-Biased Spliceosome Mutations in Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) Impair pDC Activation and Apoptosis

Katsuhiro Togami, MDPhD, Sun Sook Chung, PhD, Vikas Madan, PhD, Christopher M. Kenyon, BS, Lucia Cabal-Hierro, PhD, Justin Taylor, MD, Sunhee Kim, MD, Gabriel K Griffin, MD, Mahmoud Ghandi, Jia Li, PhD, Yvonne Y. Li, PhD, Fanny Angelot-Delletre, PhD, Sabeha Biichle, Michael Seiler, Silvia Buonamici, PhD, Scott B Lovitch, MDPhD, Abner Louissaint, Jr., MD PhD, Elizabeth A Morgan, MD, Fabrice Jardin, MD PhD, Pier Paolo Piccaluga, MD PhD, David M. Weinstock, MD, Peter S. Hammerman, MD PhD, Henry Yang, PhD, Marina Konopleva, MD PhD, Naveen Pemmaraju, MD, Francine Garnache-Ottou, PhD, Omar Abdel-Wahab, MD, H. Phillip Koeffler, MD, Andrew A Lane, MD PhD
Journal: Blood
Blood (2020) 136 (Supplement 1): 13–14.
DOI: https://doi.org/10.1182/blood-2020-137727
Published: 2020
Journal Articles

Predictors of Early Mortality, Response, and Survival in Newly Diagnosed Acute Myeloid Leukemia (AML) Using a Contemporary Academic Cohort

Patrick K Reville, MD, Graciela M. Nogueras González, MPH, Farhad Ravandi, MBBS, Koji Sasaki, MD, Gautam Borthakur, MD, Guillermo Garcia-Manero, MD, Naval Daver, MD, Courtney D. DiNardo, MD MSCE, Elias Jabbour, MD, Naveen Pemmaraju, MD, Michael Andreeff, MD PhD, Srdan Verstovsek, MD PhD, Alessandra Ferrajoli, MD, Nitin Jain, MD, Maro Ohanian, DO, Sherry A. Pierce, BSN, BA, Zeev E. Estrov, MD, Marina Konopleva, MD PhD, Hagop M. Kantarjian, MD, Tapan M. Kadia, MD
Journal: Blood
Blood (2020) 136 (Supplement 1): 44–45.
DOI: https://doi.org/10.1182/blood-2020-141837
Published: 2020